| Literature DB >> 23609016 |
Tim Heinrich1, Benjamin Rengstl, Alexander Muik, Mina Petkova, Frederike Schmid, Robin Wistinghausen, Kathrin Warner, Giuliano Crispatzu, Martin-Leo Hansmann, Marco Herling, Dorothee von Laer, Sebastian Newrzela.
Abstract
Retroviral vectors (RVs) are powerful tools in clinical gene therapy. However, stable genomic integration of RVs can be oncogenic, as reported in several animal models and in clinical trials. Previously, we observed that T-cell receptor (TCR) polyclonal mature T cells are resistant to transformation after gammaretroviral transfer of (proto-)oncogenes, whereas TCR-oligoclonal T cells were transformable in the same setting. Here, we describe the induction of a mature T-cell lymphoma (MTCL) in TCR-oligoclonal OT-I transgenic T cells, transduced with an enhanced green fluorescent protein (EGFP)-encoding gammaretroviral vector. The tumor cells were of a mature T-cell phenotype and serially transplantable. Integration site analysis revealed a proviral hit in Janus kinase 1 (Jak1), which resulted in Jak1 overexpression and Jak/STAT-pathway activation, particularly via signal transducer and activator of transcription 3 (STAT3). Specific inhibition of Jak1 markedly delayed tumor growth. A systematic meta-analysis of available gene expression data on human mature T-cell lymphomas/leukemias confirmed the relevance of Jak/STAT overexpression in sporadic human T-cell tumorigenesis. To our knowledge, this is the first study to describe RV-associated insertional mutagenesis in mature T cells.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23609016 PMCID: PMC3677306 DOI: 10.1038/mt.2013.67
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454